Business Description
Zymeworks Inc
NAICS : 325412
SIC : 2836
ISIN : CA98985W1023
Share Class Description:
ZYME: Registered ShsDescription
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.46 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.19 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 3.27 | |||||
| Beneish M-Score | -0.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.6 | |||||
| 3-Year EBITDA Growth Rate | 20.7 | |||||
| 3-Year EPS without NRI Growth Rate | 22.1 | |||||
| 3-Year FCF Growth Rate | 17.2 | |||||
| 3-Year Book Growth Rate | -9.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 14.63 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 21.1 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 75.54 | |||||
| 9-Day RSI | 68.11 | |||||
| 14-Day RSI | 65.73 | |||||
| 6-1 Month Momentum % | 49.1 | |||||
| 12-1 Month Momentum % | 86.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.01 | |||||
| Quick Ratio | 7.01 | |||||
| Cash Ratio | 6.03 | |||||
| Days Sales Outstanding | 231.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.1 | |||||
| Shareholder Yield % | 0.38 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -191.43 | |||||
| Net Margin % | -179.42 | |||||
| FCF Margin % | -153.12 | |||||
| ROE % | -25.78 | |||||
| ROA % | -20.03 | |||||
| ROIC % | -64.14 | |||||
| 3-Year ROIIC % | 101.42 | |||||
| ROC (Joel Greenblatt) % | -295.71 | |||||
| ROCE % | -24.25 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 15.67 | |||||
| PB Ratio | 2.39 | |||||
| Price-to-Tangible-Book | 2.51 | |||||
| EV-to-EBIT | -5.25 | |||||
| EV-to-EBITDA | -5.99 | |||||
| EV-to-Revenue | 10.06 | |||||
| EV-to-Forward-Revenue | 8.78 | |||||
| EV-to-FCF | -6.57 | |||||
| Price-to-Net-Current-Asset-Value | 3.54 | |||||
| Price-to-Net-Cash | 4.39 | |||||
| Earnings Yield (Greenblatt) % | -19.05 | |||||
| FCF Yield % | -9.86 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ZYME
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zymeworks Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 62.705 | ||
| EPS (TTM) ($) | -1.51 | ||
| Beta | 1.4 | ||
| Volatility % | 45.83 | ||
| 14-Day RSI | 65.73 | ||
| 14-Day ATR ($) | 0.397768 | ||
| 20-Day SMA ($) | 13.04125 | ||
| 12-1 Month Momentum % | 86.77 | ||
| 52-Week Range ($) | 6.79 - 14.05 | ||
| Shares Outstanding (Mil) | 71.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zymeworks Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zymeworks Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zymeworks Inc Frequently Asked Questions
What is Zymeworks Inc(ZYME)'s stock price today?
The current price of ZYME is $13.70. The 52 week high of ZYME is $14.05 and 52 week low is $6.79.
When is next earnings date of Zymeworks Inc(ZYME)?
The next earnings date of Zymeworks Inc(ZYME) is 2024-10-31.
Does Zymeworks Inc(ZYME) pay dividends? If so, how much?
Zymeworks Inc(ZYME) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers